BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30327172)

  • 21. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma.
    Chihara D; Fanale MA; Miranda RN; Noorani M; Westin JR; Nastoupil LJ; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Turturro F; Lee HJ; Neelapu SS; Rodriguez MA; Wang M; Fowler NH; Davis RE; Medeiros LJ; Oki Y
    PLoS One; 2018; 13(3):e0191461. PubMed ID: 29538376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.
    Hsi ED; Horwitz SM; Carson KR; Pinter-Brown LC; Rosen ST; Pro B; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Collie AM; Gruver AM; Grzywacz BJ; Turakhia S; Shustov AR; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Park SI; Foss FM
    Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):193-200. PubMed ID: 28209473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating levels of cytokines and soluble cytokine receptors in various T-cell malignancies.
    Raziuddin S; Sheikha A; Abu-Eshy S; al-Janadi M
    Cancer; 1994 May; 73(9):2426-31. PubMed ID: 8168046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic significance of lymphopenia in peripheral T-cell and natural killer/T-cell lymphomas: a study of 826 cases from the International Peripheral T-cell Lymphoma Project.
    Mitrovic Z; Perry AM; Suzumiya J; Armitage JO; Au WY; Coiffier B; Holte H; Jaffe ES; Monserrat E; Rajan SK; Savage KJ; Tobinai K; Vose JM; Weisenburger DD
    Am J Hematol; 2012 Aug; 87(8):790-4. PubMed ID: 22488678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.
    Iqbal J; Wright G; Wang C; Rosenwald A; Gascoyne RD; Weisenburger DD; Greiner TC; Smith L; Guo S; Wilcox RA; Teh BT; Lim ST; Tan SY; Rimsza LM; Jaffe ES; Campo E; Martinez A; Delabie J; Braziel RM; Cook JR; Tubbs RR; Ott G; Geissinger E; Gaulard P; Piccaluga PP; Pileri SA; Au WY; Nakamura S; Seto M; Berger F; de Leval L; Connors JM; Armitage J; Vose J; Chan WC; Staudt LM;
    Blood; 2014 May; 123(19):2915-23. PubMed ID: 24632715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study.
    Piccaluga PP; Fuligni F; De Leo A; Bertuzzi C; Rossi M; Bacci F; Sabattini E; Agostinelli C; Gazzola A; Laginestra MA; Mannu C; Sapienza MR; Hartmann S; Hansmann ML; Piva R; Iqbal J; Chan JC; Weisenburger D; Vose JM; Bellei M; Federico M; Inghirami G; Zinzani PL; Pileri SA
    J Clin Oncol; 2013 Aug; 31(24):3019-25. PubMed ID: 23857971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peripheral T cell lymphoma, not otherwise specified with myelofibrosis: report of a case with review of the literature.
    Sekiguchi Y; Shirane S; Shimada A; Ichikawa K; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
    Int J Clin Exp Pathol; 2015; 8(4):4186-203. PubMed ID: 26097612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical characteristics of angioimmunoblastic T-cell lymphoma in China and C-reactive protein as an independent prognostic factor.
    Li Y; Yang C; Mao L; Wang J; Li C; Qian W
    Medicine (Baltimore); 2017 Sep; 96(39):e8091. PubMed ID: 28953629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma.
    Yamasaki S; Chihara D; Kim SW; Kawata T; Mizuta S; Ago H; Chou T; Yamane T; Uchiyama H; Oyake T; Miura K; Saito B; Taji H; Nakamae H; Miyamoto T; Fukuda T; Kanda J; Atsuta Y; Suzuki R
    Int J Hematol; 2019 Feb; 109(2):175-186. PubMed ID: 30430419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin D deficiency is associated with inferior survival of patients with extranodal natural killer/T-cell lymphoma.
    Kim SJ; Shu C; Ryu KJ; Kang D; Cho J; Ko YH; Lee SY; Guallar E; Zhao W; Kim WS
    Cancer Sci; 2018 Dec; 109(12):3971-3980. PubMed ID: 30343526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry.
    Pedersen MB; Hamilton-Dutoit SJ; Bendix K; Møller MB; Nørgaard P; Johansen P; Ralfkiaer E; Brown Pde N; Hansen PB; Jensen BA; Madsen J; Schöllkopf C; d'Amore F
    Hematol Oncol; 2015 Dec; 33(4):120-8. PubMed ID: 25052551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified.
    ten Berge RL; de Bruin PC; Oudejans JJ; Ossenkoppele GJ; van der Valk P; Meijer CJ
    Histopathology; 2003 Nov; 43(5):462-9. PubMed ID: 14636272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.
    Reboursiere E; Le Bras F; Herbaux C; Gyan E; Clavert A; Morschhauser F; Malak S; Sibon D; Broussais F; Braun T; Fornecker LM; Garidi R; Tricot S; Houot R; Joly B; Abarah W; Choufi B; Pham AD; Gac AC; Fruchart C; Marin E; Safar V; Parcelier A; Maisonneuve H; Bachy E; Cartron G; Jaccard A; Tournilhac O; Rossi C; Schirmer L; Martignoles JA; Gaulard P; Tilly H; Damaj G;
    Oncotarget; 2016 Dec; 7(51):85573-85583. PubMed ID: 27458168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Expressions of P53, Bcl-2, and P-Glycoprotein and Prognostic Impact in Patients with Peripheral T-Cell Lymphoma (PTCL).
    Julamanee J; Kayasut K; Lekhakula A
    J Med Assoc Thai; 2015 Oct; 98(10):950-6. PubMed ID: 26638586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification.
    López-Guillermo A; Cid J; Salar A; López A; Montalbán C; Castrillo JM; González M; Ribera JM; Brunet S; García-Conde J; Fernández de Sevilla A; Bosch F; Montserrat E
    Ann Oncol; 1998 Aug; 9(8):849-55. PubMed ID: 9789607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival of Subcutaneous Panniculitis-Like T-Cell Lymphoma and Peripheral T-Cell Lymphoma Not Otherwise Specified: A Propensity-Matched Analysis of the Surveillance, Epidemiology, and End Results Database.
    Bhatt VR; Giri S; Verma V; Manandhar S; Pathak R; Bociek RG; Vose JM; Armitage JO
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):373-8. PubMed ID: 27349764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network.
    Federico M; Bellei M; Marcheselli L; Schwartz M; Manni M; Tarantino V; Pileri S; Ko YH; Cabrera ME; Horwitz S; Kim WS; Shustov A; Foss FM; Nagler A; Carson K; Pinter-Brown LC; Montoto S; Spina M; Feldman TA; Lechowicz MJ; Smith SM; Lansigan F; Gabus R; Vose JM; Advani RH;
    Br J Haematol; 2018 Jun; 181(6):760-769. PubMed ID: 29672827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.
    Rüdiger T; Weisenburger DD; Anderson JR; Armitage JO; Diebold J; MacLennan KA; Nathwani BN; Ullrich F; Müller-Hermelink HK;
    Ann Oncol; 2002 Jan; 13(1):140-9. PubMed ID: 11863096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.
    Gleeson M; Peckitt C; Cunningham D; Gibb A; Hawkes EA; Back M; Yasar B; Foley K; Lee R; Dash J; Johnson H; O'Hara C; Wotherspoon A; Attygalle A; Menasce L; Shenjere P; Potter M; Ethell ME; Dearden C; Radford J; Chau I; Linton K
    Leuk Lymphoma; 2018 Jul; 59(7):1586-1595. PubMed ID: 29119842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.
    d'Amore F; Radford J; Relander T; Jerkeman M; Tilly H; Osterborg A; Morschhauser F; Gramatzki M; Dreyling M; Bang B; Hagberg H
    Br J Haematol; 2010 Sep; 150(5):565-73. PubMed ID: 20629661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.